Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) Enterprise Value (2020 - 2025)

Historic Enterprise Value for GeneDx Holdings (WGS) over the last 6 years, with Q3 2025 value amounting to -$155.1 million.

  • GeneDx Holdings' Enterprise Value fell 3316.07% to -$155.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$155.1 million, marking a year-over-year decrease of 3316.07%. This contributed to the annual value of -$141.2 million for FY2024, which is 848.03% down from last year.
  • GeneDx Holdings' Enterprise Value amounted to -$155.1 million in Q3 2025, which was down 3316.07% from -$134.6 million recorded in Q2 2025.
  • GeneDx Holdings' Enterprise Value's 5-year high stood at $236.1 million during Q1 2021, with a 5-year trough of -$461.3 million in Q3 2021.
  • For the 5-year period, GeneDx Holdings' Enterprise Value averaged around -$163.6 million, with its median value being -$141.2 million (2024).
  • Its Enterprise Value has fluctuated over the past 5 years, first tumbled by 4036355.24% in 2021, then skyrocketed by 6906.08% in 2022.
  • GeneDx Holdings' Enterprise Value (Quarter) stood at -$400.6 million in 2021, then soared by 69.06% to -$123.9 million in 2022, then fell by 5.01% to -$130.1 million in 2023, then dropped by 8.48% to -$141.2 million in 2024, then dropped by 9.84% to -$155.1 million in 2025.
  • Its Enterprise Value was -$155.1 million in Q3 2025, compared to -$134.6 million in Q2 2025 and -$159.2 million in Q1 2025.